Clinical Trial

A Study to Assess the Efficacy and Safety of WSD0922-FU in Patients With EGFRm+ Advanced Non-small Cell Lung Cancer

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This study is a multicenter, open label, single-arm phase I/II clinical trial of WSD0922-FU for patients with locally advanced or metastatic non-small cell lung cancer whose disease has progressed with thrid-generation EGFR-TKI .
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-10-05.
Trial Details
NCT Number NCT06631989
Lead Sponsor Wayshine Biopharm, Inc.
Conditions EGFR Mutation Positive Advanced Non-Small Cell Lung Cancer
Enrollment 100 participants
Start Date 2024-09-04
Primary Completion 2027-06-30 (estimated)
Study Completion 2027-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-08-29